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Abstract
Background: The differential diagnosis between metastatic head & neck squamous cell carcinomas (HNSCC) and
lung squamous cell carcinomas (lung SCC) is often unresolved because the histologic appearance of these two
tumor types is similar. We have developed and validated a gene expression profile test (GEP-HN-LS) that
distinguishes HNSCC and lung SCC in formalin-fixed, paraffin-embedded (FFPE) specimens using a 2160–gene
classification model.
Methods: The test was validated in a blinded study using a pre-specified algorithm and microarray data files for 76
metastatic or poorly-differentiated primary tumors with a known HNSCC or lung SCC diagnosis.
Results: The study met the primary Bayesian statistical endpoint for acceptance. Measures of test performance
include overall agreement with the known diagnosis of 82.9% (95% CI, 72.5% to 90.6%), an area under the ROC
curve (AUC) of 0.91 and a diagnostics odds ratio (DOR) of 23.6. HNSCC (N = 38) gave an agreement with the known
diagnosis of 81.6% and lung SCC (N = 38) gave an agreement of 84.2%. Reproducibility in test results between three
laboratories had a concordance of 91.7%.
Conclusion: GEP-HN-LS can aid in resolving the important differential diagnosis between HNSCC and lung SCC
tumors.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1753227817890930
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Background
Metastatic squamous cell carcinomas of the head & neck
(HNSCC) and squamous cell carcinomas of the lung (lung
SCC) appear similar on microscopic examination and are
often indistinguishable using traditional histopathology.
While immunohistochemical approaches are very useful
in distinguishing squamous cell carcinomas from other
carcinomas such as adenocarcinomas, they fail to clearly
identify the site of origin of the squamous cell carcinoma
[1]. Both HNSCC and lung SCC show positive immunore-
activity with squamous cell carcinoma markers such as
p63 and CK5/6 [2].
Further confounding this diagnostic dilemma is the
fact that head & neck cancers and lung cancers often
occur in the same patient. Both cancers have similar
etiologies and risk factors such as tobacco use [3,4].
Patients with a prior laryngeal cancer also have a 4.5-fold
increased incidence ratio of lung cancer when followed for
>5 years [5]. Thus, in patients with a prior history of head
& neck cancers, a new lung lesion might represent a new
primary lung cancer or may represent metastasis from the
previously treated head & neck cancer [6,7].
The distinction between HNSCC and lung SCC, and
in particular the distinction of metastatic versus primary
cancers for lung lesions, is important for optimal clinical
management of patients. Prognosis and therapeutic
options for patients with metastatic head & neck cancer
are considerably different from those for patients with a
localized secondary lung cancer. While metastatic head &
neck cancer patients have an expected median survival of
10 months to a year, patients with solitary lung cancer
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have a median survival of 48 months [8,9]. Similarly,
therapeutic strategies for metastatic head & neck cancer
patients are markedly different from therapeutic strategies
for patients with solitary lung cancer lesions [3]. While
patients with primary lung cancers are more likely to
receive lung lobectomies, associated with a 3% mortality
rate, adjuvant chemotherapy, and other aggressive forms
of therapy, metastatic head & neck cancer patients are
more likely to be treated with palliative chemotherapy
alone [10,11].
Molecular diagnostic tests that use gene expression
profiling with microarrays to classify cancers according
to their primary sites are now a feasible tool for cancer
diagnosis [12-16]. Advances in gene annotation and
array design along with the use of standardized protocols
and array platforms across laboratories have made
microarray-based gene expression profiling highly re-
producible [13,16-19]. These assays have the advantage
of measuring the expression of a multitude of bio-
markers simultaneously. Additionally, the use of RNA
from formalin-fixed paraffin embedded (FFPE) tissue in
microarray-based diagnostics has become more com-
mon, considerably expanding the utility of these diag-
nostic tests [13,16,20-22].
Gene expression profiling has previously been used in
several studies to distinguish head & neck carcinomas
from clinically normal tissues [23-26]. These data have
been used to develop predictive models that discriminate
oral squamous cell carcinomas from normal specimens
or distinguish dysplasia from normal tissue. These models
have been validated in independent sets of samples and
shown to have high sensitivity and specificity. In contrast,
studies that use gene expression profiling to distinguish
between head & neck cancers and lung cancers have been
rare [27]. One prior study showed that histologically simi-
lar squamous cell carcinomas have distinct gene expres-
sion profiles based on their anatomic sites of origin [27].
While this profile was not validated using an independent
set of samples, it does appear that it is feasible to classify
squamous cell carcinomas based on their primary sites
using gene expression.
In order to better clarify HNSCC versus lung SCC, we
have developed a gene expression based diagnostic test,
GEP-HN-LS (PathworkW Tissue of Origin Head & Neck
Test, Pathwork Diagnostics, Inc., Redwood City, CA,
USA), that can be used to aid in the differential diagnosis
of squamous carcinomas of the head & neck and lung in
FFPE tissue. For patients with HNSCC who develop a
lung nodule, a test differentiating second primary versus
metastatic disease would have significant clinical utility.
Patients with a second primary have a high chance at
cure with aggressive therapy while patients with meta-
static disease are not curable and are best treated with
palliative chemotherapy.
Methods
FFPE tumor specimens
FFPE tumor specimens for the validation study were
acquired from seven different human tumor tissue banks
using Institutional Review Board-approved procedures.
All specimens were excisional biopsies and had a known
clinical diagnosis of lung SCC or HNSCC cancer based
on histopathology and clinical history. All specimens
had a known biopsy site and were either metastatic
tumors or primary tumors that were poorly differentiated
or undifferentiated. The anatomical sites of the primary
HNSCC cases were larynx, oral cavity, nasopharynx and
oropharynx. Esophageal carcinomas were not an included
morphology. Other available clinical information that was
recorded for each specimen included age, race, tumor
grade, cancer stage, tissue dimensions and date (year) of
resection. Further details regarding specific specimen
characteristics are included in the results. H&E sections
adjacent to the tumor sample were reviewed by a path-
ologist to determine the percentage of tumor tissue
(including stroma), normal tissue and necrosis [28]. The
pathologist assessed the tumor content by microscopic
examination of cases where the percent tumor was esti-
mated to be ≥80%. If less than 80% by visual inspection,
digital photomicrographs were made using a Zeiss
Axiocam with AxioVision software mounted on a Zeiss
AxioScope A1 microscope. The tumor and non-tumor
areas were digitally outlined and the software calculated
the areas of each. Then, percent tumor was calculated.
The GEP-HN-LS test has a specimen entry requirement
of at least 60% tumor tissue including intra-tumoral
stroma [28]. Therefore, only specimens that met this
minimal tumor content quality criterion were included
in this study. The set of specimens used for algorithm
training was completely independent from the set of
specimens used for clinical validation. Microarray data
for clinical validation specimens can be found at Gene
Expression Omnibus (GSE44177).
RNA extraction, target preparation, and microarray
processing procedures
FFPE tumor specimens were processed as described in
a previous study [13,16]. Briefly, total RNA was isolated
from 10 μm thick FFPE sections using the Agencourt
FormaPure system (Beckman Coulter Genomics, Beverly,
MA) and the Ambion DNase I RNA-free kit (Life
Technologies, Austin, TX). Total RNA concentration was
assessed by spectrophotometry (OD 260 nm, NanoDrop,
Wilmington, DE), and the purity was judged by the ratio
of absorbance at 260 nm to 280 nm (A260/A280). Thirty ng
of total RNA was amplified using the RampUp kit
(Genisphere, Hatfield, PA) to generate biotin-labeled
cDNA. Labeled cDNA was hybridized to a PathchipW
microarray (manufactured by Affymetrix, Santa Clara,
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CA), and washed and stained using commercially available
reagent kits and protocols (Affymetrix, Inc., Santa Clara,
CA). The arrays were scanned using either the Affymetrix
GCS3000Dx system or the Affymetrix 7G Scanner con-
trolled by the Affymetrix AGCC software. The resulting
raw intensity microarray data files were analyzed for
data quality.
GEP-HN-LS includes several processing quality metrics
for sample processing to continue and for a test result to
be reported out. Firstly, a minimum total RNA yield of
30 ng at a concentration of ≥9.5 ng/μl and with an A260/
A280 ratio of ≥1.0 was required to proceed to target prep-
aration. A minimum yield of 2.5 μg of labeled cDNA was
required to proceed to microarray analysis. Finally, micro-
array data quality is verified to meet prespecified quality
control metrics of Overall Signal ≥ 10, Percent Present ≥ 5,
and Regional Discontinuity ≤ 0.84, calculated as described
previously [13,16].
Specimen processing sites
All specimen preparation and processing was performed
at one of three independent processing laboratories:
Pathwork Diagnostics Laboratory (Redwood City, CA),
Expression Analysis (Durham, NC) and GeneLogic, Inc
(Gaithersburg, MA). Pathwork Diagnostics Laboratory
and GeneLogic, Inc processed specimens for the clinical
validation study; inter-site reproducibility was assessed at
Pathwork Diagnostics Laboratory (Site #1), Expression
Analysis (Site #2) and GeneLogic, Inc (Site #3); intra-
site repeatability (precision) was assessed at Pathwork
Diagnostics Laboratory. Laboratories performing the test
were blinded to the known clinical diagnosis. All micro-
array data files were transferred to Pathwork Diagnostics
for data quality assessment and analysis through GEP-
HN-LS.
Algorithm development
The GEP-HN-LS test standardization algorithm was de-
veloped by evaluating >5000 tissue specimens from a
range of tissue types that were processed at 11 laborator-
ies. The classification algorithm was developed using a
database of 249 lung SCC and 242 HNSCC specimens
that had a known lung SCC or HNSCC cancer diagnosis
based on clinical history. Similar to the validation speci-
mens, the training set specimens were a mixture of pri-
mary and metastatic cancers with the majority of the
cases being primary cancers. In contrast to the validation
specimens, where the primary cancers were restricted to
poorly differentiated and undifferentiated cases, the
training set included a large number of well and moder-
ately differentiated cancers. Among the metastatic cases,
lymph node was the primary biopsy site. Other biopsy
sites included brain, abdominal wall and dermal tissues.
A machine learning approach was used to select the
optimal model for classifying lung SCC and HNSCC
cancers. To minimize overfitting in the presence of a
high number of predictors and a relatively small training
set, we applied nested cross-validation approach, which
is to the best of our knowledge state-of-the-art method
in the context of small sample size/high dimensional
problems common in genomics [29]. Validation results
on the independent clinical set of previously unseen
specimens confirmed that the method adequately pre-
vented excessive overfitting. The optimal model con-
sisted of a list of 2600 probe-sets (2160 independent
genes) and a set of coefficients that are combined to
produce 2 Similarity Scores. The 2 Similarity Scores
correspond to the probability that the gene expression
profile of the input specimen matches the expression pro-
file of lung SCC and HNSCC cancers. The standardization
and classification algorithms were locked prior to initi-
ation of clinical validation studies.
Test report
The Test report (Figure 1) is interpreted using the fol-
lowing guide to report interpretation: The Similarity
Score (SS) is a measure of the similarity of the RNA ex-
pression pattern of the specimen to the RNA expression
patterns of lung SCC and HNSCC tumor tissues. Two
SS are generated, one for lung SCC origin and one for
HNSCC origin. The scores add up to 100. The higher
the SS, the more likely it represents the tissue of origin
of the cancer.
Clinical validation study design
GEP-HN-LS clinical validation study used Bayesian
adaptive analysis to determine the design plan and sam-
ple sizes [30,31]. Details regarding the clinical validation
study design and sample size estimates are provided in
Additional file 1: Methods and Table S1. Briefly, the
study was designed to have no greater than 5% Type I
error and at least 98% power to meet prespecified ac-
ceptance criteria. The criteria are based on the mean
positive percent agreement (mean PPA) between the
Test prediction and the available clinical diagnosis. The
acceptance criteria were: mean PPA must be at least 80%
and the lower bound of the 95% credible interval must
be at least 65%. These requirements were derived from
analyses of the training data, requirements for clinical
utility of the test, and practicality of obtaining sufficient
number of specimens. The study design used three phases,
commonly referred to as Looks. Look 1 used one half of
the maximum sample size; Look 2 used three-quarters of
the maximum sample size; and Look 3 used the maximum
sample size. The study design allowed for early termin-
ation based on intermediate analyses after each look.
Study termination at each look could occur if the accept-
ance criteria were met or if the predicted probability of
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success at the maximum sample size, based on the data
accumulated up to that point, was less than 5%.
Reproducibility study design
The intra-site (precision) and inter-site reproducibility of
GEP-HN-LS was assessed as follows: For intra-site repro-
ducibility (precision), three adjacent 10 μm thick sections
from FFPE tissue blocks of 16 specimens (lung SCC = 8;
HNSCC= 8) that gave an agreement with the known clin-
ical diagnosis were processed simultaneously within the
same run. For inter-site reproducibility, three adjacent
10 μm thick sections from FFPE tissue blocks of 30 speci-
mens (lung SCC = 15; HNSCC= 15) that gave an agree-
ment with the known clinical diagnosis were processed at
each of the three laboratories in this study. Concordance
in GEP-HN-LS results obtained from pairwise compari-
sons of the three sections was used as a measure of test re-
producibility for both the intra-site and inter-site analysis.
Details regarding sample size estimates for the reproduci-
bility study are provided in Additional file 1: Methods.
Data analysis
Mean PPA and credible intervals are Bayesian parameters
that were used as the primary endpoint for the GEP-HN-
LS clinical validation study (see Additional file 1: Methods
for details). Performance of the Test was measured as the
positive percent agreement (PPA) which is defined as the
percent agreement between the GEP-HN-LS test result
and the known clinical diagnosis. A receiver operator curve
was plotted and AUC was calculated using SigmaPlot 12
[32]. The diagnostic odds ratio was calculated to provide a
single indicator of test performance as described earlier
[33]. For intra-site and inter-site reproducibility, results
were considered concordant if the GEP-HN-LS test results
from one section or site matched the result from another
section or site. In both cases, an overall pairwise percent
concordance in GEP-HN-LS test results is reported. Kappa
statistics for agreement were calculated for pairwise com-
parisons using R Version 2.11.1 (2010-05-31) [34].
Results
The GEP-HN-LS test
The GEP-HN-LS test indicates whether HNSCC or lung
SCC is the more likely tissue of origin. The test relies on
two distinct algorithms, one for standardization and one
for classification. The standardization algorithm is used to
normalize the raw probe-level intensity values of the gene
expression profiles under analysis and reduce technical
variation incurred by different processing conditions. The
standardized expression values for each probe-set gener-
ated by the standardization algorithm are used by the
GEP-HN-LS classification algorithm. The classification
model measures the expression of 2600 probesets (2160
independent genes) that serve as markers during classifi-
cation of lung SCC and HNSCC cancers; and produce 2
Similarity Scores that correspond to the probability that
the gene expression profile of the input specimen matches
the expression profile of lung SCC and HNSCC cancers.
The classification markers are empirically selected by
machine learning. Nonetheless, they included several
genes that have a known function in lung biology
(Table 1). The top five probesets were from surfactant
proteins that have a biophysical function in the lung and
have a role in pulmonary host defense and regulation of
inflammation [35,36]. Expression of specific surfactant
proteins in squamous cell carcinomas is controlled by
DNA methylation and may be involved in lung cancer
pathogenesis [37,38].
Figure 1 A sample GEP-HN-LS Test report. The report presents 2 Similarity Scores, one for head & neck squamous cell cancer (HNSCC) and
one for lung squamous cancer (lung SCC) cancers. The two Similarity Scores add up to 100. The tissue type with the higher Similarity Score is the
more likely tissue of origin. In the sample shown, HNSCC cancer with a Similarity Score of 71.1 is the more likely tissue of origin.
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Processing of clinical validation specimens
Tissue sections from 80 specimens were processed for
total RNA. Thirty nanograms of total RNA is required
to perform the GEP-HN-LS Test. All 80 specimens
yielded at least 30 ng of total RNA at a concentration of
≥9.5 ng/μl and had a median A260/A280 ratio of 1.94
(range 1.56-2.60) and were processed further. All 80
specimens yielded at least 2.5 μg of biotinylated cDNA
and were hybridized to Pathchip microarrays. Of the 80
specimens, 76 specimens passed pre-specified microarray
data quality criteria as described in the Methods Section.
In all, 95.0% (76/80) of FFPE specimens processed passed
all quality criteria for the GEP-HN-LS Test. Data from
these 76 specimens were used in data analysis.
Performance of GEP-HN-LS
The clinical validation study followed a Bayesian adap-
tive design. Testing was terminated at Look2 after pro-
cessing of 76 specimens because the acceptance criteria
of mean PPA and lower bound of the 95% credible inter-
val for both lung SCC and HNSCC cancers exceeded
pre-specified threshold values at this interim analysis
(Additional file 1: Table S2). The positive percent agree-
ment (PPA) and percent non-agreement with 95% confi-
dence intervals for GEP-HN-LS are summarized in
Table 2. The overall agreement of the GEP-HN-LS test re-
sults with the known clinical diagnosis was 82.9% (95% CI,
72.5% to 90.6%). Lung SCC cancers had a higher PPA of
84.2% compared to HNSCC cancers that had a PPA of
81.6% (Fisher’s exact test, p = 1.000; Table 2).
A discrepancy analysis was performed to assess the
cause of the disagreements of the 13 cases with the ref-
erence diagnosis. All available clinical and pathology in-
formation for the 13 disagreements and a representative
set of cases that gave agreements with the reference
diagnosis were reviewed by an independent pathologist
who was blinded to the test results. None of the cases
could be categorized as ‘definitely not the reference diag-
nosis’. Thus, the reference diagnosis was as accurate as
possible with available clinical data and current diagnos-
tic methods.
An ROC for GEP-HN-LS was plotted and an AUC of
0.91 was obtained indicating high discriminatory perform-
ance between lung SCC and HNSCC cancers (Figure 2A).
Table 1 Top 20 biomarkers in the GEP-HN-LS test classification algorithm
Marker
rank
Probeset ID Gene
symbol
Gene name Tissue type with higher
expression levels
1 218835_at* SFTPA2 surfactant protein A2 Lung
2 209810_at* SFTPB surfactant protein B Lung
3 37004_at* SFTPB surfactant protein B Lung
4 214387_x_at* SFTPC surfactant protein C Lung
5 211735_x_at* SFTPC surfactant protein C Lung
6 211024_s_at* NKX2-1 NK2 homeobox 1 (TTF-1) Lung
7 205927_s_at CTSE cathepsin E Lung
8 205654_at C4BPA complement component 4 binding protein, alpha Lung
9 209351_at KRT14 keratin 14 Head & Neck
10 205916_at S100A7 S100 calcium binding protein A7 Head & Neck
11 205778_at KLK7 kallikrein-related peptidase 7 Head & Neck
12 211538_s_at HSPA2 heat shock 70 kDa protein 2 Head & Neck
13 206697_s_at HP haptoglobin Lung
14 209616_s_at CES1 carboxylesterase 1 Lung
15 211429_s_at SERPINA1 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin),
member 1
Lung
16 213553_x_at APOC1 apolipoprotein C-I Lung
17 204424_s_at LMO3 LIM domain only 3 (rhombotin-like 2) Lung
18 206008_at TGM1 transglutaminase 1 (K polypeptide epidermal type I, protein-glutamine
-gamma-glutamyltransferase)
Head & Neck
19 218644_at PLEK2 pleckstrin 2 Head & Neck
20 202017_at EPHX1 epoxide hydrolase 1, microsomal (xenobiotic) Lung
*Known to have a role in lung biology.
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The diagnostic odds ratio of 23.6 (95%CI, 7.1 to 78.2) also
indicated that GEP-HN-LS had good discrimination be-
tween lung SCC and HNSCC cancers.
A distribution plot of the HNSCC similarity scores in
bins of 10 for the 76 clinical validation specimens is
plotted in Figure 2B. Since the sum of the similarity
scores for HNSCC and lung SCC tissue types is 100, the
higher HNSCC similarity scores correspond to lower
lung SCC similarity scores and vice versa. The median
higher similarity score for cases that gave agreements
with the known clinical diagnosis (n = 63) was 96.8
(range, 51.5, 100) for the matched origin and 3.2 (range, 0,
48.5) for the excluded site of origin. In contrast, cases that
gave a non-agreement with the known clinical diagnosis
(n = 13) had a median higher similarity score for the
mismatched origin that was lower at 75.9 (range, 51.1,
100). Sixty one percent (46 of 76) of the specimens
assessed gave a similarity score of ≥ 90. For these speci-
mens, the test result indicated the correct HNSCC or lung
SCC tissue 95.7% (95% CI: 85.2-99.5) of the time. This also
indicates that a similarity score of ≤ 10 rules out that tissue
type with a >95% probability (95% CI: 85.2-99.5). Among
the HNSCC predictions, 20/37 specimens had a similarity
score of ≥ 90 with 19/20 agreements while 26/29 speci-
mens that gave lung SCC predictions had a similarity
score of ≥ 90 with 25/26 agreements.
Performance of GEP-HN-LS according to specimen attributes
The specimens used for clinical validation were acquired
in the prior 5 years (Table 3). The age of the specimen
did not affect Test performance. For entry into the GEP-
HN-LS test, specimens are required to have at least 60%
tumor content. The remaining 40% of the specimen
could be normal or necrotic tissue. Test performance
was consistent at all levels of viable percent tumor above
the minimal threshold of ≥ 60% tumor content (Table 3).
Specimens in the 60% to 70% tumor content bin had a
PPA of 81.8%. The presence of up to 40% necrosis in the
specimen under analysis did not diminish performance
of GEP-HN-LS (Table 3). In fact, the three specimens in
the validation set that had 30 to 40% necrotic content
gave agreements with the available clinical diagnosis.
Performance of GEP-HN-LS according to patient and
cancer attributes
The age range of patients from whom validation speci-
mens were obtained was wide. GEP-HN-LS had good
performance for all patient age groups (Table 4). The
grade of the cancer was known for 70/76 cases included
in the validation study. Since primary tumors in the val-
idation set were solely composed of poorly differentiated
to undifferentiated cancers, the vast majority of cases
were Grade 3 cancers. GEP-HN-LS had an accuracy of
82.1% for these poorly differentiated Grade 3 specimens
(Table 4). Representative poorly differentiated HNSCC
and lung SCC cases that were indistinguishable by hist-
ology and immunohistochemistry but were accurately
classified by GEP-HN-LS are shown in Figure 3. The
TNM Stage was known for 33/76 cases included in the
validation study. GEP-HN-LS performance was equiva-
lent and good for Stage I – II and Stage III – IV cancers.
Table 2 Accuracy of GEP-HN-LS
Known clinical
diagnosis
Positive percent
agreement
Percent non-
agreement
Percent (ratio) Percent (ratio)
[95% Confidence
Interval]
[95% Confidence
Interval]
Head & Neck Squamous 81.6 (31/38) 18.4 (7/38)
[65.7-92.3] [7.7-34.3]
Lung Squamous 84.2 (32/38) 15.8 (6/38)
[68.7-94.0] [6.0-31.3]
Overall 82.9 (63/76) 17.1 (13/76)
[72.5-90.6] [9.4-27.5]
Figure 2 Performance of GEP-HN-LS. A receiver operator curve
(ROC) curve (A) for the GEP-HN-LS Test using results from the
independent validation specimens gives an area under the curve
(AUC) value of 0.91. Distribution of Similarity Scores (B) obtained for
the validation specimens show separation of the head & neck
squamous cell (HNSCC) cancers and lung squamous cancer
(lung SCC) predictions.
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GEP-HN-LS performance was good with both metastatic
specimens (80.8%; n = 26) and with poorly differentiated
primary tumors (84.0%; n = 50) (Table 4). For metastatic
samples, lymph node was the most common biopsy site
constituting 80.7% (21/26) of all metastatic cases. Eighty
one percent (17/21) of the specimens that metastasized to
lymph nodes gave an agreement with the available diagno-
sis (Table 4). These lymph node metastases included both
HNSCC and lung SCC specimens suggesting that GEP-
HN-LS could distinguish HNSCC and lung SCC in lymph
nodes. The remaining metastatic specimens were biopsied
from brain, abdominal wall and dermal tissues. Represen-
tative metastatic HNSCC and lung SCC cases harboring
well-differentiated squamous cell morphologic appearances
are shown in Figure 3. GEP-HN-LS could clearly distin-
guish between these morphologically similar cancers.
Reproducibility of the GEP-HN-LS test
Intra-site reproducibility (precision) was assessed by
performing pairwise comparisons of GEP-HN-LS test
Table 3 GEP-HN-LS performance according to specimen
attributes
Specimen attributes No. of
specimens
PPA
Percent (ratio)
[95% Confidence Interval]
Age of Specimen
<1 year 37 78.4 (29/37)
[61.8-90.2]
1-2 year 8 87.5 (7/8)
[47.3-99.7]
2-3 year 8 87.5 (7/8)
[47.3-99.7]
3-4 year 12 83.3 (10/12)
[51.6-97.9]
4-5 year 11 90.9 (10/11)
[58.7-99.8]
Percent Tumor Content
90% < x≤ 100% 7 85.7 (6/7)
[42.1-99.6]
80% < x≤ 90% 19 94.7 (18/19)
[74.0-99.9]
70% < x≤ 80% 28 75.0 (21/28)
[55.1-89.3]
60%≤ x≤ 70% 22 81.8 (18/22)
[59.7-94.8]
Percent Necrosis
0%≤ x < 10% 39 82.1 (32/39)
[66.5-92.5]
10%≤ x < 20% 19 84.2 (16/19)
[60.4-96.6]
20%≤ x < 30% 15 80.0 (12/15)
[51.9-95.7]
30%≤ x≤ 40% 3 100 (3/3)
[29.2-100]
Abbreviations: PPA, Positive percent agreement; No. of Specimens, Number of
specimens in each category.
Table 4 GEP-HN-LS test performance according to patient
and cancer attributes
Patient/cancer
attribute
No. of
specimens
Overall PPA
Percent (ratio)
[95% Confidence Interval]
Age of Patient (years)
40-50 16 87.5 (14/16)
[61.7-98.4]
50-60 25 80.0 (20/25)
[59.3-93.2]
60-70 25 80.0 (20/25)
[59.3-93.2]
>70 10 90.0 (9/10)
[55.5-99.7]
Cancer Grade
Grade 1 4 100.0 (4/4)
[39.8-100.0]
Grade 2 10 80.0 (8/10)
[44.4-97.5]
Grade 3 56 82.1 (46/56)
[69.6-91.1]
Cancer Stage
I-II 16 75.0 (12/16)
[47.6-92.7]
III-IV 17 82.3 (14/17)
[56.6-96.2]
Primary Versus Metastatic Cancer
Metastatic 26 80.8 (21/26)
[60.6-93.4]
Primary 50 84.0 (42/50)
[70.9-92.8]
Biopsy Sites for Metastatic Cases
Lymph Node 21 81.0 (17/21)
[58.1-94.6]
Other 5 80.0 (4/5)
[28.4-99.5]
Abbreviations: PPA, positive percent agreement; No. of Specimens, Number of
specimens in each category.
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results obtained from 3 adjacent sections from the same
tissue block processed in the same run. Overall percent
concordance in test results was 91.4% (Table 5). The
median percent coefficient of variation of the similarity
score for the known clinical diagnosis was 3.26% (range
0.0 to 64.3). Discordant specimens were outliers and
gave the highest percent coefficient of variation. The
value of Kappa (κ) statistics was 0.84, 0.81 and 0.81 for
the three pairwise comparisons indicating very good
(κ ≥ 0.81) agreement in GEP-HN-LS test results be-
tween sections processed in the same run.
Pairwise comparisons of GEP-HN-LS test results for ad-
jacent sections from 30 specimens processed at three
laboratories (PWDL, EA and GLGC) were performed to
assess inter-site reproducibility. The percent concordance
in test results for PWDL versus EA was 90.0%, for PWDL
versus GLGC was 92.6% and for EA versus GLGC was
92.6% (Table 5). The median percent coefficient of vari-
ation of the similarity score for the known clinical diag-
nosis was 3.12% (range - 0.00 to 66.8%). Once again,
discordant samples were outliers and gave the highest
percent coefficient of variation. Kappa (κ) statistics for
agreement for PWDL versus EA was 0.80 (95% CI, 0.56-
1.00), for PWDL versus GLGC was 0.85 (95% CI, 0.62-1.00)
and for EA versus GLGC was 0.85 (95% CI, 0.63-1.00),
indicating good (κ = 0.61 – 0.80) or very good agreement
(κ ≥ 0.81) in GEP-HN-LS test results between the three sites.
Discussion
Squamous cell carcinomas originating in the lung and
those originating in the head & neck region are mor-
phologically similar. Additionally, there are no known
Figure 3 Distinction of head & neck squamous cell carcinoma (HNSCC) and lung squamous carcinoma (lung SCC) cancers by GEP-HN-
LS. H&E stained sections (A and B) of a metastatic lung SCC carcinoma (A) and a metastatic HNSCC carcinoma (B) from the validation
specimens show well-differentiated squamous cell morphologic appearance. GEP-HN-LS clearly distinguished between these metastatic tumors.
GEP-HN-LS test results were lung SCC with a Similarity Score of 82.6 for the metastatic lung SCC cancer (A) and HNSCC with a Similarity Score of
99.1 for the metastatic HNSCC cancer (Photographs A and B taken at 10X objective magnification). Both poorly differentiated lung SCC (C, E) and
HNSCC (D, F) cancers from the validation specimens show positive immunohistochemical staining for p63 (C, D) and CK5/6 (E, F), common
biomarkers for squamous cell carcinomas. GEP-HN-LS test results for these cancers were lung SCC with a Similarity Score of 100 for the poorly
differentiated lung SCC cancer (C, E) and HNSCC with a Similarity Score of 93.8 for the poorly differentiated HNSCC cancer (D, F) (Photographs C, D, E
and F taken at 20× objective magnification; Bars equal 50 μm).
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immunohistochemical markers that can identify the
tissue of origin of squamous cell carcinomas. GEP-
HN-LS, a novel gene expression profile diagnostic
test, can successfully distinguish between lung SCC and
HNSCC cancers. Performance was evaluated in an inde-
pendent set of specimens that were solely composed of ei-
ther metastatic cancers or poorly differentiated primary
cancers. GEP-HN-LS accurately identified the primary site
of lung or head & neck in 82.9% of cases with a known
clinical diagnosis of squamous cell carcinoma. The majority
of specimens had Similarity Scores of ≥ 90 and for these
specimens GEP-HN-LS indicated the correct HNSCC or
lung SCC tissue 95.7% of the time. Physicians utilizing the
GEP-HN-LS test receive both the tissue type result and the
similarity score, and can evaluate the confidence of the tis-
sue call based on the similarity score. The data presented in
this study support the superiority of GEP-HN-LS in dis-
tinguishing HNSCC from lung SCC when compared to hu-
man papillomavirus (HPV) testing, which has low
sensitivity as it is present in only a subset of HNSCC [26].
Cytokeratin profiling has not been useful in distinguishing
between squamous cell carcinomas from various primary
sites as squamous cancers have overlapping cytokeratin
positivity profiles.
GEP-HN-LS uses 2600 probesets (2160 independent
genes) to classify HNSCC and lung SCC cancers. These
classification biomarkers were empirically chosen based
upon maximal performance observed with the training
data and the 20 markers with the highest predictive
value included several genes with specific functions in
lung biology and possible roles in lung cancer. Sur-
factant proteins are components of the lipoprotein sur-
factant complex that reducing surface tension at the
alveolar air-liquid interface and facilitate respiratory me-
chanics [35,36]. They control pulmonary host defense
and inflammation, and might have a role in lung cancer
pathogenesis [37,38]. Interestingly, NKX2-1 (more com-
monly known as Thyroid Transcription Factor-1 or
TTF-1), a common immunohistochemical marker of
lung adenocarcinomas [39,40], was among the top 20
classification markers and had higher expression levels
in lung SCC compared to HNSCC cancers. Squamous
cell carcinomas are typically negative for nuclear NKX2-
1 protein expression [41]. However, cytoplasmic staining
of the NKX2-1 protein and expression of the NKX2-1
transcript has been observed in squamous cell carcin-
omas [42].
Gene expression profiling has previously been success-
fully used to distinguish between primary lung cancers
and metastatic head and neck cancers [27]. The top clas-
sification markers identified in the prior study were dif-
ferent from those used by GEP-HN-LS. This is possibly
because the prior study utilized frozen tissues and the
GEP-HN-LS test is optimized to work on FFPE speci-
mens. In addition, the prior study utilized a different
microarray chip and restricted the head & neck cases to
those occurring in the oral tongue which is not the most
common head and neck cancer subtype [27]. Another
study used gene expression profiling to identify differ-
ences between head & neck and cervical cancers, the
majority of which are also squamous cell cancers [26].
Kallikrien-related peptidase 7, KLK7, was the only
marker in our list of top classification markers that was
among their differentially expressed genes. Thus, this
gene had higher expression levels in HNSCC compared
to both lung SCC and cervical cancers.
Gene expression profiling based predictive models that
distinguish oral squamous cell carcinomas from normal
tissue and oral dysplasia from normal tissue have also
been developed [23-26]. The classification markers used
by these prior models are distinct from those used by
GEP-HN-LS. This is not surprising since the prior
models identify the presence of cancer while GEP-HN-
LS differentiates between two different cancers.
GEP-HN-LS utilizes FFPE specimens, the most com-
monly available clinical specimen and success rates for
processing FFPE specimens was 95.0%. The use of FFPE
specimens along with a high processing success rate is
advantageous in the clinical setting, and allows for wide
usage of GEP-HN-LS.
Table 5 Reproducibility of GEP-HN-LS
Study Concordance Discordance
Percent (ratio) Percent (ratio)
[95% Confidence
Interval]
[95% Confidence
Interval]
Intra-Site Reproducibility
Section # 2 versus Section #3 92.3 (12/13) 7.7 (1/13)
[64.0-99.8] [0.2-36.0]
Section # 2 versus Section # 4 90.9 (10/11) 9.1 (1/11)
[58.7-99.8] [0.2-41.3]
Section # 3 versus Section # 4 90.9 (10/11) 9.1 (1/11)
[58.7-99.8] [0.2-41.3]
Overall 91.4 (32/35) 8.6 (3/35)
[76.9-98.2] [1.8-23.1]
Inter-Site Reproducibility
Site # 1 versus Site # 2 90.0 (27/30) 10.0 (3/30)
[73.5-97.9] [2.1-26.5]
Site # 1 versus Site # 3 92.6 (25/27) 7.4 (2/27)
[75.7-99.1] [0.9-24.3]
Site # 2 versus Site # 3 92.6 (25/27) 7.4 (2/27)
[75.7-99.1] [0.9-24.3]
Overall 91.7 (77/84) 8.3 (7/84)
[83.6-96.6] [3.4-16.4]
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The test has been validated for samples that have as
low as 60% tumor content. In cases where the tumor
content of specimens is <60%, tissue microdissection
can be used to enrich the tumor content and achieve the
60% tumor requirement. FFPE specimens used in this
study were excisional biopsies. However, FFPE cell but-
tons from fine needle aspirates (FNA), including bone
marrow aspirates, FFPE cell buttons from malignant ef-
fusions and FFPE core needle biopsies can be used with
GEP-HN-LS as long as they contain ≥ 60% tumor and
yield sufficient (≥ 30 ng) total RNA to allow target prep-
aration. Test performance of GEP-HN-LS was consistent
regardless of the biopsy site. Both primary and meta-
static cases, which have different biopsy sites, performed
well with GEP-HN-LS. While our study was not pow-
ered to perform sub-population analysis, GEP-HN-LS
could distinguish specific cases of HNSCC versus lung
SCC that were both in the lymph node. Additionally, test
performance for specimens with a lymph node biopsy
site was equivalent to specimens with other biopsy sites
such as brain or skin.
Since this test has high accuracy and reliability we feel
it can be used in a clinical setting. In patients who are
newly diagnosed with a solitary lung nodule at the same
time as locally advanced HNSCC this test can be used to
determine if the patient has two simultaneous primaries
or metastatic HNSCC. For patients with two primaries,
aggressive therapy for both areas is recommended since
cure rates remain high, while metastatic patients should
receive only palliative therapies. Similarly, for patients
previously treated for HNSCC who on follow-up scans
are noted to have a lung nodule, GEP-HN-LS test can be
used to determine if this new nodule is metastatic dis-
ease or a second primary, for patients with second pri-
maries aggressive surgical resection is indicated.
In this study, we present data validating the accuracy
and reproducibility of GEP-HN-LS. The test can be used
as an adjunct to histologic and clinical information for
difficult to diagnose patients where the distinction be-
tween squamous lung cancer and squamous head &
neck cancer would impact surgical or drug management
of these patients. We anticipate GEP-HN-LS to have
particular clinical value for patients with a lung lesion
and a history of prior head & neck cancers and for pa-
tients with a new diagnosis of HNSCC diagnosed with a
concurrent lung lesion. In these cases, the test would aid
in distinguishing between a new lung primary or meta-
static disease.
Conclusion
In summary, in the current study, we have validated per-
formance of the GEP-HN-LS test. This test has potential
to be a valuable ancillary tool for physicians as they
diagnose and make clinical management decisions for
head & neck and lung cancer patients.
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